InhaleRx Limited (IRX.AX)
AUD 0.04
(0.0%)
AUD 0.04
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -155.54 Thousand AUD | 92.71% |
| 2022 | -2.13 Million AUD | 23.9% |
| 2021 | -2.8 Million AUD | -63.04% |
| 2020 | -1.71 Million AUD | -304.62% |
| 2019 | -424.95 Thousand AUD | 81.63% |
| 2018 | -2.31 Million AUD | 48.02% |
| 2017 | -4.45 Million AUD | 41.51% |
| 2016 | -7.61 Million AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -14.01 Thousand AUD | 90.99% |
| 2024 Q2 | -14.01 Thousand AUD | 0.0% |
| 2023 FY | -155.54 Thousand AUD | 92.71% |
| 2023 Q1 | -433.98 Thousand AUD | 79.66% |
| 2023 Q2 | -433.98 Thousand AUD | 0.0% |
| 2023 Q3 | -155.54 Thousand AUD | 64.16% |
| 2023 Q4 | -155.54 Thousand AUD | 0.0% |
| 2022 Q4 | -2.13 Million AUD | -0.0% |
| 2022 Q2 | -1.89 Million AUD | 0.0% |
| 2022 FY | -2.13 Million AUD | 23.9% |
| 2022 Q1 | -1.89 Million AUD | 32.5% |
| 2022 Q3 | -2.13 Million AUD | -12.73% |
| 2021 Q1 | -3.45 Million AUD | -100.71% |
| 2021 FY | -2.8 Million AUD | -63.04% |
| 2021 Q3 | -2.8 Million AUD | 18.77% |
| 2021 Q2 | -3.45 Million AUD | 0.0% |
| 2021 Q4 | -2.8 Million AUD | 0.0% |
| 2020 Q3 | -1.71 Million AUD | -253.03% |
| 2020 FY | -1.71 Million AUD | -304.62% |
| 2020 Q4 | -1.71 Million AUD | 0.0% |
| 2020 Q2 | -487.05 Thousand AUD | 0.0% |
| 2020 Q1 | -487.05 Thousand AUD | -14.62% |
| 2019 Q2 | -1.32 Million AUD | 0.0% |
| 2019 Q1 | -1.32 Million AUD | 42.95% |
| 2019 FY | -424.95 Thousand AUD | 81.63% |
| 2019 Q4 | -424.92 Thousand AUD | 0.0% |
| 2019 Q3 | -424.92 Thousand AUD | 67.82% |
| 2018 Q3 | -2.31 Million AUD | 30.2% |
| 2018 Q1 | -3.31 Million AUD | 26.58% |
| 2018 FY | -2.31 Million AUD | 48.02% |
| 2018 Q4 | -2.31 Million AUD | 0.0% |
| 2018 Q2 | -3.31 Million AUD | 0.0% |
| 2017 Q1 | -5.81 Million AUD | 0.0% |
| 2017 Q4 | -4.51 Million AUD | 0.0% |
| 2017 FY | -4.45 Million AUD | 41.51% |
| 2017 Q2 | -5.81 Million AUD | 0.0% |
| 2017 Q3 | -4.51 Million AUD | 22.29% |
| 2016 Q2 | -273.05 Thousand AUD | 0.0% |
| 2016 FY | -7.61 Million AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| 4DMedical Limited | -25.48 Million AUD | 99.39% |
| Adherium Limited | -6.1 Million AUD | 97.452% |
| Aroa Biosurgery Limited | -3.74 Million AUD | 95.849% |
| Atomo Diagnostics Limited | -3.6 Million AUD | 95.683% |
| Anteris Technologies Ltd | -28.49 Million AUD | 99.454% |
| Control Bionics Limited | -19.02 Thousand AUD | -717.706% |
| CardieX Limited | 2.74 Million AUD | 105.664% |
| Compumedics Limited | 5.08 Million AUD | 103.058% |
| Cochlear Limited | -269.9 Million AUD | 99.942% |
| CleanSpace Holdings Limited | 698.59 Thousand AUD | 122.265% |
| Cyclopharm Limited | -7.49 Million AUD | 97.926% |
| EMVision Medical Devices Ltd | -15.7 Million AUD | 99.009% |
| Nova Eye Medical Limited | -2.8 Million AUD | 94.449% |
| HeraMED Limited | -799.34 Thousand AUD | 80.541% |
| Imricor Medical Systems, Inc. | 14.48 Million AUD | 101.074% |
| ImpediMed Limited | -23.48 Million AUD | 99.338% |
| LBT Innovations Limited | -604 Thousand AUD | 74.248% |
| Micro-X Limited | 826.99 Thousand AUD | 118.808% |
| Neurotech International Limited | -2.11 Million AUD | 92.63% |
| OncoSil Medical Limited | -4.43 Million AUD | 96.489% |
| PolyNovo Limited | -30.52 Million AUD | 99.49% |
| Respiri Limited | 413.68 Thousand AUD | 137.599% |
| SomnoMed Limited | -15.16 Million AUD | 98.974% |
| Universal Biosensors, Inc. | -5.3 Million AUD | 97.067% |
| Uscom Limited | -1.53 Million AUD | 89.838% |
| Visioneering Technologies, Inc. | -4.08 Million AUD | 96.19% |